Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Lundbeck

    - PMLiVE

    Mission Therapeutics advances Parkinson’s disease candidate

    The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK

    - PMLiVE

    PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s

    The US-based company develops light-based therapies for neurodegenerative conditions

    - PMLiVE

    GSK and Vesalius partner on new Parkinson’s treatments in deal worth $650m

    The alliance is aimed at developing treatments for Parkinson's and another neurodegeneration indication

    - PMLiVE

    Researchers develop AI blood test to predict Parkinson’s seven years before symptom onset

    The neurodegenerative condition currently affects nearly ten million people worldwide

    - PMLiVE

    Cerevel Therapeutics shares positive phase 3 results for tavapadon in Parkinson’s disease

    The progressive neurodegenerative disease affects seven million people worldwide

    - PMLiVE

    Co-funded trial shows promise for Sanofi’s diabetes drug in early Parkinson’s disease

    According to WHO, the neurodegenerative disease affected more than 8.5 million people worldwide in 2019

    - PMLiVE

    Two UK clinical trials launched to identify blood tests for dementia diagnosis

    The neurodegenerative condition affects more than 944,000 people in the UK

    - PMLiVE

    NeuroDerm shares positive phase 3 results for investigational Parkinson’s disease therapy

    The progressive neurodegenerative disease affects around ten million people worldwide

    - PMLiVE

    AbbVie’s Produodopa rolled out by NHS England for advanced Parkinson’s patients

    The roll out follows NICE’s recommendation of the treatment in October 2023

    - PMLiVE

    Michael J Fox Foundation awards Vesper Bio over $870,000 for Parkinson’s treatment

    Vesper is currently developing VES001 for GRN-mutated frontotemporal dementia

    - PMLiVE

    New framework establishes two tests for use in clinical trials for Parkinson’s

    The neurological condition currently affects around 145,000 people in the UK

    - PMLiVE

    Researchers develop new blood test to identify risk of Parkinson’s disease

    The findings could help to identify people most likely to benefit from disease-modifying therapies

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links